Elimination of xenobiotics in a female patient with fibromyalgia, chronic fatigue and trunk obesity;Xenobiotikaausleitung bei einer patientin mit fibromyalgie, chronischer erschöpfung und stammbetonter adipositas

Forschende Komplementarmedizin

Volumn 14, Issue 1, 2007, Pages 39-44

  Mutter, J ^a   Naumann, J ^a   Guethlin, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adrenocortical insufficiency, secondary; Aluminium; Detoxification; Fatigue; Fibromyalgia; Isolated ACTH deficiency; Mercury; Vaccination

Indexed keywords

CHELATING AGENT; XENOBIOTIC AGENT;

ACUPUNCTURE; ADRENAL CORTEX INSUFFICIENCY; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC FATIGUE SYNDROME; CONSTIPATION; DIET THERAPY; DISEASE DURATION; EDEMA; ENVIRONMENTAL FACTOR; FEMALE; FIBROMYALGIA; FOLLICULITIS; HUMAN; MYOFASCIAL PAIN; OBESITY; SUPPLEMENTATION; TINNITUS;

ACUPUNCTURE THERAPY; ADULT; CHELATING AGENTS; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; FATIGUE SYNDROME, CHRONIC; FEMALE; FIBROMYALGIA; HUMANS; OBESITY; TREATMENT OUTCOME;

EID: 33847627497     PISSN: 16614119     EISSN: 16614127     Source Type: Journal    
DOI: 10.1159/000099128     Document Type: Article

References (42)

1. Bircher-Benner M: Ordnungsgesetze des Lebens als Wegweiser zur echten Gesundheit. Bad Homburg, Bircher-Benner, 1984.
2. Schnitzer JG: Intensivkost und Normalkost. St. Georgen, Schnitzer, 1978.
3. Aposhian HV: Mobilization of mercury and arsenic in humans by sodium 2,3-dimercapto-1-propane sulfonate (DMPS). Environ Health Perspect 1998;106(suppl 4):1017-1025.
4. Mutter J, Naumann J, Schneider R, Walach H, Haley B: Mercury and autism: Accelerating evidence? Neuroendocrinol Lett 2005;26:439-446.
5. Autism Research Institute (ed): Treatment options for mercury/metal toxicity in autism and related developmental disabilities. 2005, www.autismwebsite.com/ari/treatment/form34q.htm.
6. Bruker MO: Unsere Nahrung - unser Schicksal. Lahnstein, emu, 1986.
7. Cornett CR, Ehmann WD, Wekstein DR, Markesbery WR: Trace elements in Alzheimer's disease pituitary glands. Biol Trace Elem Res 1998;62:107-114.
8. Lorscheider FL, Vimy MJ, Summers AO: Mercury exposure from 'silver' tooth fillings: Emerging evidence questions a traditional dental paradigm. FASEB J 1995;9:504-508.
9. Eggleston DW, Nylander M: Correlation of dental amalgam with mercury in brain tissue. J Prosthet Dent 1987;58:704-707.
10. Nylander M: Mercury in pituitary glands of dentists. Lancet 1986;1:442.
11. Nylander M, Friberg L, Lind B: Mercury concentrations in the human brain and kidneys in relation to exposure from dental amalgam fillings. Swed Dent J 1987;11:179-187.
12. Lorscheider FL, Vimy MJ: Mercury exposure from 'silver' fillings. Lancet 1991;337:1103.
13. Guzzi G, Grandi M, Cattaneo C, et al: Dental amalgam and mercury levels in autopsy tissues. Food for thought. Am J Forensic Med Pathol 2006;27:42-45.
14. Drasch G, Schupp I, Riedl G, Günther G: Einfluß von Amalgamfüllungen auf die Quecksilberkonzentration in menschlichen Organen. Dtsch Zahnärztl Z 1992;47:490-496.
15. Mutter J, Naumann J, Walach H, Daschner F: Amalgam: Eine Risikobewertung unter Berücksichtigung der neuen Literatur bis 2005. Gesundheitswesen 2005;67:204-216.
16. Mutter J, Naumann J, Walach H, Daschner F: Risikobewertung Amalgam: Antwort auf Prof. Halbachs Kommentar. Gesundheitswesen 2006;68:277. www.thieme-connect.de/ejournals/html/gesu/doi/10.1055/s-2006-926707.
17. Halbach S: Entwarnung in Sachen Amalgam. Apotheken Umschau 2/2005:16-18.
18. Halbach S: Risikobewertung Amalgam. Gesundheitswesen 2006;68:277. Extended version: www.thieme-connect.de/ejournals/html/gesu/doi/10.1055/s-2006- 926707.
19. Harhammer R: Zur Risikobewertung des zahnärztlichen Füllungswerkstoffes Amalgam. Bundesgesundheitsbl 2001;44:149-154.
20. Bailer J, Rist F, Rudolf A, Staehle HJ, Eickholz P, Triebig G, Bader M, Pfeifer U: Adverse health effects related to mercury exposure from dental amalgam fillings: Toxicological or psychological causes? Psychol Med 2001;31:255-263.
21. Bailer J, Staehle HJ, Rist F: Ill due to amalgam? 10 rules for managing the symptomatic patient. MMW Fortschr Med 2003;145:34-38.
22. Lindh U, Hudecek R, Danersund A, Eriksson S, Lindvall A: Removal of dental amalgam and other metal alloys supported by antioxidant therapy alleviates symptoms and improves quality of life in patients with amalgam-associated ill health. Neuroendocrinol Lett 2002;23:459-482.
23. Haley BE: Mercury toxicity: Genetic susceptibility and synergistic effects. Med Ver 2005;2:535-542.
24. Petrik MS, Wong MC, Tabata RC, Garry RF, Shaw CA: Aluminium adjuvant linked to gulf war illness induces motor neuron death in mice. Neuromolecular Med 2007;9:83-100.
25. Kihira T, Yoshida S, Komoto J, Wakayama I, Yase Y: Aluminum-induced model of motor neuron degeneration: Subperineural injection of aluminum in rabbits. Neurotoxicology 1995;16:413-424.
26. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellissier JF, Chariot P, Authier FJ: Macrophagic myofasciitis lesions assess longterm persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001;24:1821-1831.
27. Mutter J, Naumann J, Sadaghiani C, Schneider R, Walach H: Alzheimer Disease: Mercury as pathogenetic factor and apolipoprotein E as a moderator. Neuroendocrin Lett 2004;25:275-283.
28. Godfrey ME, Wojcik DP, Krone CA: Apolipoprotein E genotyping as a potential biomarker for mercury neurotoxicity. J Alzheimers Dis 2003;5:189-195.
29. Wojcik DP, Godfrey ME, Christie D, Haley BE: Mercury toxicity presenting as chronic fatigue, memory impairment and depression: Diagnosis, treatment, susceptibility, and outcomes in a New Zealand general practice setting (1994-2006). Neuroendocrinol Lett 2006;27:415-423.
30. Stewart WF, Schwartz BS, Simon D, Kelsey K, Todd AC: ApoE genotype, past adult lead exposure, and neurobehavioral function. Environ Health Perspect 2002;110:501-505.
31. Geier M, Geier D: A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders. Hormone Res 2006;66:182-188.
32. Stejskal J, Stejskal VD: The role of metals in autoimmunity and the link to neuroendocrinology. Neuroendocrinol Lett 1999;20:351-364.
33. Valentine-Thon E, Schiwara HW: Validity of MELISA for metal sensitivity testing. Neuroendocrinol Lett 2003;24:57-64.
34. Regland B, Zachrisson O, Stejskal V: Nickel allergy is found in a majority of women with chronic fatigue syndrome and muscle pain and may be triggered by cigarette smoking and dietary nickel intake. J Chron Fatigue Synd 2001;8:57-65.
35. Stejskal VD, Danersund A, Lindvall A, Hudecek R, Nordman V, Yaqob A, Mayer W, Bieger W, Lindh U: Metal-specific lymphocytes: biomarkers of sensitivity in man. Neuroendocrinol Lett 1999;20:289-298.
36. Thomas P, Summer B, Przybilla B: Allergische Reaktionen auf Metallimplantate. Dtsch Ärztebl 2001;30:971-974
37. Valentine-Thon E: Clinical relevance of lymphocyte transformation (LTT-MELISA) for detecting and monitoring metal sensitivity. Neuroendocrinol Lett 2007;in press.
38. Valentine-Thon E, Schiwara HW: Metallsensibilisierung: Nachweis, Validierung und Verlaufskontrolle mittels Lymphozyten-Test. Z Orthomolecular Med 2005;1:12-15.
39. Sterzl I, Prochazkova J, Hrda P, Matucha P, Bartova J, Stejskal VD: Removal of dental amalgam decreases anti-TPO and anti-Tg autoantiodies in patients with autoimmune thyreoiditis. Neuroendocrinol Lett 2006;27(suppl 1).
40. Sterzl I, Prochazkova J, Hrda P, Bartova J, Matucha P, Stejskal VD: Mercury and nickel allergy: risk factors in fatigue and autoimmunity. Neuroendocrinol Lett 1999;20:221-228.
41. Prochazkova J, Sterzl I, Kucerova H, Bartova J, Stejskal VDM: The beneficial effect of amalgam replacement on health in patients with autoimmunity. Neuroendocrinol Lett 2004;25:211-218.
42. Yaqob A, Danersund A, Stejskal VD, Lindvall A, Hudecek R, Lindh U: Metal-specific lymphocyte reactivity is downregulated after dental metal replacement. Neuroendocrinol Lett 2006;27:189-197.